In the TME, tumour-derived TGF-β inhibits IFN-α, TNF-α, and IL-6 production in tumour-associated plasmacytoid dendritic cells (pDCs) to foster their immune tolerance functions [131]. Here, TGFB1 is linked to neoplasm.